 |
||
 |
 |
 |
| PGNX - (NASDAQ)
$3.91 - 0.11 |
May 22, 2013
4:00 PM ET |
Latest News
May 17, 2013
Progenics Pharmaceuticals Added to the NASDAQ Biotechnology Index
May 10, 2013
Progenics Pharmaceuticals Announces First Quarter 2013 Financial Results
May 6, 2013
Progenics Pharmaceuticals to Host Conference Call to Review First Quarter 2013 Financial Results on May 10
For the complete U.S. package insert for RELISTOR, please visit www.relistor.com 
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions.
Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer.
Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.